Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
London pre-open: Flat start expected as nerves set in
(Sharecast News) - UK stocks are expected to open flat on Tuesday as investors continue to act cautiously ahead of some pivotal central bank meetings later this week. Futures on IG's platform show just a 0.03% fall on the FTSE 100 in pre-market trading.
The index retreated from a four-month high on Monday on the back of rising oil prices and nervousness ahead of the Federal Reserve and Bank of England policy meetings on Wednesday and Thursday, respectively. The Fed is widely expected to leave interest rates unchanged, while the BoE is set to hike rates by another 25 basis points to 5.5%.
Brent crude was up a further 0.5% on Tuesday at $94.90 a barrel as it continues to flirt with its yearly high of $99.56.
The economic data agenda for Tuesday looked relatively light, with consumer price inflation data from the Eurozone, and US housing starts and building permits the only major things to watch out for.
In company news, online grocer and technology company Ocado maintained annual guidance after a 7.2% rise in third-quarter retail revenues. The company, 50% owned by Marks & Spencer, said retail sales came in at £569.6m from £531m a year earlier, with a return to positive volume growth in the last month of the quarter.
Pharmaceutical giant GSK announced that its Apretude drug for HIV prevention has received approval from the European Commission. ViiV Healthcare, a specialist HIV company co-owned by GSK, Pfizer and Shionogi (GSK is the majority shareholder), showed in a clinical trial that Apretude demonstrated "superior efficacy" to the standard daily oral PrEP option in reducing the risk of acquiring HIV, and only needs to be taken as few as six times a year.
Hargreaves Lansdown reported a net new business gain of £4.8bn and an 8% increase in assets under administration to £134bn in its results for the year ended 30 June. The savings and investment company reported a rise of 67,000 active clients, bringing the total to 1,804,000. Furthermore, profit before tax surged by 50% to £402.7m, with the ordinary dividend increasing by 4.5% to 41.5p per share.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.